Hikal Limited — Updates, 07-08-2025: Press Release

Hikal Ltd. reported Q1 FY26 revenue of Rs 380 Cr, EBITDA of Rs 25 Cr, and a PAT loss of Rs (23) Cr. The decline was mainly due to deferred pharma offtake following a USFDA Official Action Indicated (OAI) at its Bangalore facility. The company is actively addressing this with a remediation partner. Positively, ANVISA (Brazil) and PMDA (Japan) audits at Bangalore concluded successfully. Crop protection revenue was flat at Rs 178 Cr, facing margin pressure. Hikal is expanding into Personal Care, Specialty Chemicals, and Animal Health, and anticipates a recovery in Q3/Q4 FY26, reaffirming its full-year guidance.